Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients

BMC Research Notes

Table 2 Association between MSN and claudin7 immunoexpression and the clinical variables

Variables (group 1 vs group2)	MSN			Claudin7
	P value	Odds Ratio	CI	P value	Odds Ratio	CI
Age*	0.206			0.196
Stage^	0.29	1.401	0.741-2.664	1	1.033	0.546-1.962
Tumor size^	0.013	2.305	1.168-4.724	0.759	0.876	0.456-1.673
Lymho-vascular involvement^	0.098	0.616	0.344-1.096	0.413	1.255	0.707-2.236
Lymph node status	1	1.018	0.47-2.2	0.365	0.685	0.314-1.48
Depth of myometrial invasion^	0.305	1.323	0.776-2.262	0.442	0.797	0.467-1.358
Grade_FIGO^	< 0.001	2.561	1.501-4.41	< 0.001	0.389	0.226-0.665
Grade_nuclear^	< 0.001	2.557	1.504-4.385	0.001	0.419	0.245-0.711
Subtype#	< 0.001	0.311	0.154-0.609	0.002	2.628	1.353-5.253
Recurrence#	0.867	0.935	0.456-1.925	0.309	1.479	0.722-3.061
Recurrence^	0.867	0.928	0.454-1.903	0.401	1.383	0.678-2.852
Status#	0.567	0.847	0.462-1.554	0.112	1.623	0.885-3.007
Status^	1	1.015	0.468-2.226	0.278	1.53	0.705-3.386

^ The P-values by Fisher exact test to test the correlations between the biomarker and the clinical factors.
* The P-value is calculated by the two sample welch t-test
Stage: Group1: stages I and II; Group 2: stages III and IV
Tumor Size: Group 1:< = 2 cm; Group2: > 2 cm
LVI: Group 1:yes; Group2: no
Depth of myometrial invasion: Group1:< = 50; Group2:> 50
Grade: Group1: grade 1 and 2; Group2; grade 3
Subtype#: Group1:CCC & USC; Group 2: Endometrioid; Group3: MMMT
Recurrence#: Group1:yes; Group2:no; Group3:others
Recurrence^: Group1:yes; Group2: no &others
Status#: Group1: ANED; Group2: all others
Status^: Group1:ANED&AWED; Group2: all others
Interprete the Odds Ratio:
> 1, the proportion of p and n biomarkers status in Group 2 is greater than the proportion in Group 1
< 1, the proportion of p and n biomarkers status in Group 1 is greater than the proportion in Group 2

ISSN: 1756-0500